A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors

Inclusion Criteria: * Men and women 18 and older * Diagnosis of any solid tumor * ECOG performance status score 0-1 * Prior chemo-therapy, immunotherapy or radiotherapy with at least 4 weeks since the last treatment * Treatment with VEGFR2 or HER1 TKI allowed but not both (for instance Avastin or Tarceva, but not both) Exclusion Criteria: * Treatment with other TKIs within the past 4 weeks * Patients with brain metastasis * Patients with centrally located squamous cell carcinoma of the lung * Major gastrointestinal surgery which may affect absorption of the drug * Any surgery within last 4 weeks * History of thromboembolism * Severe unmanageable diarrhea * Subjects in Part B will have Non-Small Cell Lung Cancer (NSCLC) * Part B/Cohort I erlotinib-naive subjects * Part B/Cohort II subjects who have experienced disease progression while receiving erlotinib (erlotinib-resistant subjects)